Make An Appointment

Or
Physician Location Contact

Prostate Cancer Clinical Trials

Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males worldwide. Treatment aimed at eradicating the primary tumor, typically with surgery or radiation, is unsuccessful in 30% of men, who develop recurrent disease that usually manifests first as a rise in plasma prostate specific antigen (PSA) followed by spread to distant sites.  

Given that prostate cancer cells depend on androgen receptor (AR) for their proliferation and survival, the standard treatment for subjects with recurrent disease is to lower the level of testosterone with a gonadotropin releasing hormone analog (GnRHa) (or surgical castration), block androgen binding to the AR with an anti-androgen, or both. The results are predictable, with a decline in PSA followed by tumor regression, a period of stability in which tumor burden and PSA remain stable, followed by rising PSA and regrowth as a castration-resistant lesion.

If you are currently receiving ADT (androgen deprivation therapy) like Lupron and Firmagon and your PSA continues to rise, you may be eligible to participate in one of our clinical trials. In addition patients diagnosed with advanced Prostate Cancer (cancer that has spread to distant sites) may be eligible.

For eligibility purposes please be advised that medical records will be requested and reviewed for confirmation.

If you think you might qualify for our Prostate Cancer Clinical Trials please email ClinicalTrials@skyuro.com or call 424-212-4580 and a research coordinator will respond to your request.

Learn more about Prostate Cancer